A
Alexandros Ardavanis
Researcher at Yahoo!
Publications - 145
Citations - 2937
Alexandros Ardavanis is an academic researcher from Yahoo!. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 27, co-authored 130 publications receiving 2521 citations.
Papers
More filters
Journal ArticleDOI
Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
Andreas Scorilas,Andreas Karameris,Niki Arnogiannaki,Alexandros Ardavanis,P Bassilopoulos,Theoni Trangas,Maroulio Talieri +6 more
TL;DR: MMP-9 status was compared with the concentration of cytosolic Cathepsin-D and with other established prognostic factors, in terms of disease free survival and overall survival and it is suggested that M MP-9 may be an independent favourable prognostic factor in node-negative breast cancer patients.
Journal ArticleDOI
A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer
Eleni G. Iliopoulou,Panteleimon Kountourakis,Michalis V. Karamouzis,Dimitrios Doufexis,Alexandros Ardavanis,Constantin N. Baxevanis,Gerasimos Rigatos,Michael Papamichail,Sonia A. Perez +8 more
TL;DR: In conclusion, repetitive infusions of allogeneic, in vitro activated and expanded with IL-15/HC NK cells, in combination with chemotherapy are safe and potentially clinically effective.
Journal ArticleDOI
The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias
Flora Tzifi,Christina Economopoulou,Dimitrios Gourgiotis,Alexandros Ardavanis,Sotirios G. Papageorgiou,Andreas Scorilas +5 more
TL;DR: Current knowledge on the role of BCL2 apoptosis regulator proteins in acute and chronic leukemias is described to lead to the design of new therapies which may improve patients' survival.
Journal ArticleDOI
Vinorelbine Plus Cisplatin Versus Docetaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial
Vassilis Georgoulias,Alexandros Ardavanis,X. Tsiafaki,A. Agelidou,Penelope Mixalopoulou,Ourania Anagnostopoulou,P. Ziotopoulos,Michael Toubis,Kostas N. Syrigos,Nikolaos Samaras,Aris Polyzos,Anna Christou,Stylianos Kakolyris,Charalambos Kouroussis,Nikolaos Androulakis,George Samonis,Dora Chatzidaki +16 more
TL;DR: Although the two regimens produced comparable overall survival, the DG regimen had a better toxicity profile and could be used in the first-line setting of advanced NSCLC, especially for patients who cannot tolerate cisplatin.
Journal ArticleDOI
CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients.
Sonia A. Perez,Michael V. Karamouzis,Dimosthenes V. Skarlos,Alexandros Ardavanis,Nectaria N. Sotiriadou,Eleni G. Iliopoulou,Maria Salagianni,George Orphanos,Constantin N. Baxevanis,Gerasimos Rigatos,Michael Papamichail +10 more
TL;DR: Treg cell frequency does not directly correlate with clinical stage in breast cancer, as stage III and IV HER+ and HER− patients exhibit significantly different Treg profiles.